IDH1 was a key rate-limiting enzyme in the Krebs cycle (28, 29), and IDH1 mutation was a favorable independent prognostic factor for PFS in glioma (9, 10), and it also played an important role in the time of tumor recurrence and outcome of gliomas. The gene discussed is IDH1; the disease is neoplasm.